On May 22, 2025 Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported the poster presentation of two abstracts at the 2025 American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 30-June 3 in Chicago (Press release, Bicycle Therapeutics, MAY 22, 2025, View Source [SID1234653296]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:

Title: Phase 1/2 Duravelo-1 study: Preliminary results of Nectin-4-targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer
Poster Session: Genitourinary Cancer—Kidney and Bladder
Date and Time: Monday, June 2, at 9 a.m.-12 p.m. CT
Abstract Number: 4567
Lead Author: Patrizia Giannatempo, M.D., Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy

Title: A phase 2/3 study of Bicycle Drug Conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC; Duravelo-2)
Poster Session: Genitourinary Cancer—Kidney and Bladder
Date and Time: Monday, June 2, at 9 a.m.-12 p.m. CT
Abstract Number: TPS4619
Lead Author: Yohann Loriot, M.D., Ph.D., Gustave Roussy Institute, University Paris-Saclay, Villejuif, France

The posters will be made available in the Publications section of the Bicycle Therapeutics website at the beginning of the poster session.